Status:
UNKNOWN
New Techniques to evAlUate Response to neOadjuvant Treatments in bReast cAncer (AURORA)
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The role of neoadjuvant chemotherapy (NAC) in breast cancer is well established. Increasing rates of pathologic complete response (pCR) has increased de-escalation of surgical techniques. The objectiv...
Detailed Description
The role of neoadjuvant chemotherapy (NAC) in breast cancer is well established. In inoperable patients at the time of diagnosis, the goal of NAC is to achieve a pathologic complete response (pCR) whi...
Eligibility Criteria
Inclusion
- Women with Pathologic diagnosis of breast cancer with indication of neoadjuvant chemotherapy
Exclusion
- Breast cancer recurrence
- Other synchronic tumour.
- Inflammatory cancer.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04795349
Start Date
December 1 2020
End Date
December 1 2022
Last Update
March 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clínica Universidad de Navarra
Madrid, Spain, 28027